METTL4: A Potential Drug Target and Biomarker (G64863)

Target Name: METTL4

NCBI ID: G64863

METTL4

METTL4: A Potential Drug Target and Biomarker

Methylation is a critical epigenetic modification that plays a crucial role in cellular processes, including DNA replication, gene expression, and cellular signaling. Imbalances in methylation have been implicated in numerous diseases, including cancer, neurodegenerative diseases, and developmental disorders. One promising target for the regulation of methylation is the methyltransferase METTL4, which has been identified as a potential drug target and biomarker.

METTL4 is a non-coding RNA molecule that belongs to the METTL family of methyltransferases. METTL4 is primarily expressed in the brain and has been shown to play a role in the regulation of neuronal excitability and synaptic plasticity. METTL4 has also been shown to be involved in the regulation of cellular processes that are critical for brain development and function, including neuronal cell death, cell proliferation, and migration.

Recent studies have suggested that METTL4 may be a drug target for several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and their dysfunction. METTL4 has been shown to be involved in the regulation of neurodegenerate diseases by modifying the expression of genes that are critical for neuronal survival and function.

In addition to its potential role in neurodegenerative diseases, METTL4 has also been shown to be involved in several other biological processes that are relevant to human health. For example, METTL4 has been shown to play a role in the regulation of cancer cell proliferation and has been identified as a potential biomarker for cancer. Additionally, METTL4 has been shown to be involved in the regulation of cellular signaling pathways that are critical for cellular growth, differentiation, and survival.

Another promising aspect of METTL4 is its potential as a drug target is its ability to modulate the expression of genes that are involved in several diseases, including cancer, neurodegenerative diseases, and developmental disorders. METTL4 has been shown to interact with several transcription factors, including NF-kappa-B, AP-1, and STAT3. These transcription factors play a critical role in regulating gene expression and are involved in the development and progression of many diseases. By modulating the expression of these genes, METTL4 has been shown to have a wide range of potential therapeutic applications.

In conclusion, METTL4 is a promising target for drug development due to its involvement in the regulation of methylation and its potential role in the development and progression of neurodegenerative diseases. Furthermore, METTL4 has also been shown to be involved in the regulation of cellular signaling pathways and has the potential to act as a biomarker for several diseases. Further research is needed to fully understand the role of METTL4 in these processes and to develop effective therapies based on this target.

Protein Name: Methyltransferase 4, N6-adenosine

Functions: N(6)-adenine-specific methyltransferase that can methylate both RNAs and DNA (PubMed:31913360, PubMed:32183942). Acts as a N(6)-adenine-specific RNA methyltransferase by catalyzing formation of N6,2'-O-dimethyladenosine (m6A(m)) on internal positions of U2 small nuclear RNA (snRNA): methylates the 6th position of adenine residues with a pre-deposited 2'-O-methylation (PubMed:31913360). Internal m6A(m) methylation of snRNAs regulates RNA splicing (PubMed:31913360). Also able to act as a N(6)-adenine-specific DNA methyltransferase by mediating methylation of DNA on the 6th position of adenine (N(6)-methyladenosine) (PubMed:32183942). The existence of N(6)-methyladenosine (m6A) on DNA is however unclear in mammals, and additional evidences are required to confirm the role of the N(6)-adenine-specific DNA methyltransferase activity of METTL4 in vivo (PubMed:32203414). Acts as a regulator of mitochondrial transcript levels and mitochondrial DNA (mtDNA) copy number by mediating mtDNA N(6)-methylation: m6A on mtDNA reduces transcription by repressing TFAM DNA-binding and bending (PubMed:32183942). N(6)-methyladenosine deposition by METTL4 regulates Polycomb silencing by triggering ubiquitination and degradation of sensor proteins ASXL1 and MPND, leading to inactivation of the PR-DUB complex and subsequent preservation of Polycomb silencing (By similarity)

The "METTL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets